Lineage Cell Therapeutics, Inc.

NYSEAM:LCTX Stock Report

Market Cap: US$316.6m

Lineage Cell Therapeutics Management

Management criteria checks 4/4

Lineage Cell Therapeutics' CEO is Brian Culley, appointed in Sep 2018, has a tenure of 7.75 years. total yearly compensation is $2.11M, comprised of 32.8% salary and 67.2% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth $324.49K. The average tenure of the management team and the board of directors is 4.8 years and 9.6 years respectively.

Key information

Brian Culley

Chief executive officer

US$2.1m

Total compensation

CEO salary percentage32.77%
CEO tenure7.8yrs
CEO ownership0.1%
Management average tenure4.8yrs
Board average tenure9.6yrs

Recent management updates

Recent updates

Narrative Update • Jun 03

LCTX: AlloSCOPE Pipeline And Ophthalmology Data Will Support Future Upside Potential

Analysts have lifted their price target on Lineage Cell Therapeutics by $0.36 to $5.50, citing updated assumptions around potential revenue growth, profit margins, and a lower future P/E multiple following recent bullish coverage and a $1 target increase from B. Riley.
New Narrative • May 23

Cell Therapy Manufacturing And Partner Dependence Will Pressure Margins Yet Leave Long Runway

Catalysts About Lineage Cell Therapeutics Lineage Cell Therapeutics develops allogeneic cell therapies using its AlloSCOPE manufacturing platform for conditions linked to loss of specific cell function. What are the underlying business or industry changes driving this perspective?
Narrative Update • Apr 29

LCTX: AlloSCOPE Platform Progress Will Support Future Pipeline Monetization Potential

Analysts have raised their price target on Lineage Cell Therapeutics by $1, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E that reflect recent bullish coverage and target revisions from the Street. Analyst Commentary Bullish Takeaways Bullish analysts point to recent target revisions as support for a higher fair value, suggesting that prior assumptions for revenue growth, profit margins, and future P/E were conservative.
Narrative Update • Aug 06

Aging Trends And Regenerative Medicine Will Open New Avenues

Lineage Cell Therapeutics' higher net profit margin and a slight increase in its discount rate have contributed to a raised consensus analyst price target, now at $4.17. What's in the News First-ever chronic spinal cord injury patient treated in Lineage's DOSED clinical study, which evaluates a novel device for delivering OPC1 cells directly to injury sites; OPC1 has received RMAT and Orphan Drug designations from the FDA.
User avatar
New Narrative • May 18

Advancements In OpRegen And Genentech Collaborations Will Unlock Potential

Strong data support and partnership expansions, especially for OpRegen, could significantly enhance future revenue and market share in dry AMD.

CEO Compensation Analysis

How has Brian Culley's remuneration changed compared to Lineage Cell Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$64m

Dec 31 2025US$2mUS$692k

-US$64m

Sep 30 2025n/an/a

-US$68m

Jun 30 2025n/an/a

-US$41m

Mar 31 2025n/an/a

-US$16m

Dec 31 2024US$3mUS$665k

-US$19m

Sep 30 2024n/an/a

-US$20m

Jun 30 2024n/an/a

-US$24m

Mar 31 2024n/an/a

-US$24m

Dec 31 2023US$3mUS$640k

-US$21m

Sep 30 2023n/an/a

-US$23m

Jun 30 2023n/an/a

-US$22m

Mar 31 2023n/an/a

-US$24m

Dec 31 2022US$2mUS$609k

-US$26m

Sep 30 2022n/an/a

-US$49m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$49m

Dec 31 2021US$3mUS$580k

-US$43m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$14m

Dec 31 2020US$1mUS$552k

-US$21m

Sep 30 2020n/an/a

-US$27m

Jun 30 2020n/an/a

-US$36m

Mar 31 2020n/an/a

-US$59m

Dec 31 2019US$773kUS$536k

-US$12m

Compensation vs Market: Brian's total compensation ($USD2.11M) is about average for companies of similar size in the US market ($USD2.48M).

Compensation vs Earnings: Brian's compensation has been consistent with company performance over the past year.

CEO

Brian Culley (55 yo)

7.8yrs
Tenure
US$2,111,170
Compensation

Mr. Brian M. Culley, M.A., M.B.A., served as Interim Chief Financial Officer, Principal Financial Officer at Lineage Cell Therapeutics, Inc. since July 8, 2022 until November 14, 2022. He served as Interim...

Leadership Team

NamePositionTenureCompensationOwnership
Brian Culley
CEO, President & Director7.8yrsUS$2.11m0.10%
$ 324.5k
Jill Howe
Chief Financial Officer3.6yrsUS$1.01m0.010%
$ 32.4k
George Samuel
General Counsel & Company Secretary4.8yrsUS$978.23k0.012%
$ 39.4k
Ioana Hone
Director of Investor Relationsno datano datano data
Charlotte Hubbert
Vice President of Corporate Strategy & Development2.2yrsno datano data
Priyantha Herath
Senior VP & Head of Clinical Operationsless than a yearno datano data
Rami Skaliter
Chief Executive Officer of Cell Cure Neurosciencesno datano datano data
Alexandra Hernandez
Senior Director of Finance & Controller6.8yrsno datano data
Harold Waitz
Vice President of Regulatory Affairs & Quality Control31.4yrsUS$90.00kno data
4.8yrs
Average Tenure
55yo
Average Age

Experienced Management: LCTX's management team is considered experienced (4.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Brian Culley
CEO, President & Director7.8yrsUS$2.11m0.10%
$ 324.5k
Angus Russell
Independent Director11.5yrsUS$120.99k0.035%
$ 111.1k
Anula Jayasuriya
Independent Director5.1yrsUS$103.49k0.0040%
$ 12.7k
Neal Bradsher
Independent Director16.9yrsUS$118.49k0.035%
$ 111.3k
Deborah Andrews
Independent Director12.2yrsUS$123.49k0.0063%
$ 19.8k
Michael Mulroy
Independent Chairman11.7yrsUS$160.99k0.12%
$ 379.2k
Dipti Amin
Independent Director5.2yrsUS$103.49k0.014%
$ 44.5k
Joachim Fruebis
Founding Member of Scientific Advisory Boardless than a yearno datano data
9.6yrs
Average Tenure
62yo
Average Age

Experienced Board: LCTX's board of directors are considered experienced (9.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/15 11:23
End of Day Share Price 2026/06/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lineage Cell Therapeutics, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Mayank MamtaniB. Riley Securities, Inc.
John NewmanCanaccord Genuity